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INTRODUCTION 
Cancer chemotherapy is challenged with the problem of 
delivering the required therapeutic concentration of the 
drug at the tumor site for the desired period of time 
without causing undesirable effects on other organs after 
systemic administration.
1,2,3
 
Targeted delivery of anticancer 
drugs to solid tumors, therefore, is necessary in order to 
achieve optimum therapeutic outcomes. Nanoscale devices 
has led to the development of biodegradable self-
assembled nanoparticles, which are being engineered for 
the targeted delivery of anticancer drugs and imaging 
contrast agents capable of ferry ing large doses of 
chemotherapeutic agents into malignant cells sparing the 
healthy cells.  
Tamoxifen citrate, the nonsteroidal antiestrogen is the 
treatment of choice for patients with all stages of estrogen 
receptor positive breast cancer.
4,5
 Tamoxifen belongs to a 
class of nonsteroidal triphenylethylene derivatives and is 
considered the first selective estrogen receptor 
modulator.
6,7
 The drug exhibits anti-estrogenic activity by 
binding to the intracellular estrogen receptor.
8
 
The 
Tamoxifen-estrogen receptor complex binds with DNA 
and can alter or block subsequent mRNA transcription and 
lead to cellular apoptosis.
9,10 
Tamoxifen has some major side effects following long-
term therapy in postmenopausal  breast cancer patients,  
including higher incidence of endometrial cancer, liver 
cancer, thromboembolic disorders, and development of 
drug resistance.
11 
Tamoxifen resistance has been shown in 
a variety of cells in vitro as well as in vivo.
12 
 
These 
unwanted side effects of Tamoxifen, as well as various 
barriers to the delivery of the drugs to tumor, call for 
targeted delivery to the tumor site and enhanced uptake by 
the tumor cells. One approach to overcome the undesirable 
side effects of Tamoxifen includes the use of 
biodegradable polymeric nanoparticles for tumor-targeted 
drug delivery. Tamoxifen has been formulated in 
nanoparticulate carrier systems in the form of nanospheres 
such as poly-ε-caprolactone nanoparticles and long-
circulat ing PEG-coated poly(MePEG cyanoacrylate- 
cohexadecylcyanoacrylate) nanoparticles in the form of 
free base.
13,14
 It is known that the tumor vasculature is 
leaky and possesses an enhanced capacity for the uptake of 
macromolecules and colloidal drug carriers of up to 400 
nm in diameter. Th is effect is known as the enhanced 
permeability and retention (EPR) effect.
15,16,17 
Thus, such a 
delivery method could improve the selectivity of treatment 
by increasing the ratio of tamoxifen absorbed by the tumor 
ABSTRACT 
The present investigation was aimed to study the antiproliferative action of Tamoxifen citrate (TMX), a non 
steroidal antiestrogen, on a human T-cell leukemia cell line, Jurkat, as free drug and TMX loaded guar gum 
nanoparticles. For this we developed a new formulation containing chemically cross-linked guar gum nanoparticles  
(GG NPs) loaded with Tamoxifen citrate (TMX). Single step (oil in water) emulsion and in-situ polymer cross-
linking technique was employed to prepare spherical and smooth surfaced nanoparticles in the size range of 200-
300nm. Nanoparticle size and shape was confirmed from observation in transmission electron microscope (TEM) 
analysis. Cytotoxicity on Jurkat (human T-cell leukemia) cell lines as determined by cell growth inhibition after 48 
hrs of incubation indicated that Tamoxifen citrate loaded guar gu m nanoparticles were as efficient as the free drug 
when applied to the cancer cells. However, the crosslinked guar gum nanoparticles loaded with Tamoxifen citrate 
exhibited sustained release of the drug and delayed apoptosis over a long period of time making it suitable for cancer 
treatment.  
Keywords: Nanoparticles, guar gum, Tamoxifen citrate, Jurkat (human T-cell leukemia) cell line, cytotoxicity, cell 
death, WST-1 assay. 
 
 
Jayanta et al                                       Journal of drug delivery & Therapeutics, 2(2), 2012                                                    68 
© 2011, JDDT. All Rights Reserved                                                                                                                                  ISSN: 2250-1177 
to tamoxifen absorbed by other tissues, leading to a 
reduction in the systemic side effects.  
On the other hand, the coating with polymers provides 
sustained release along with protection of the active drug 
from gastric fluid.
18,19
 
Polysaccharides, the polymers of 
monosaccharides, retain their integrity in the upper 
gastrointestinal tract because they are resistant to the 
digestive action of gastrointestinal enzymes. The 
polysaccharide, guar gum, obtained from the seeds of 
Cyamposis tetragonolobus, is a low cost, easily available, 
non toxic, biodegradable polymer. It consists of linear 
chains of (1→4)β-D-manopyranosy1 units with β-D-
galactopyranosy1 units attached by (1→6) linkages.20 Guar 
gum is hydrophilic in nature and swells in cold water 
forming viscous colloidal dispersions or sols. This gelling 
property retards release of the drug from the dosage form 
which makes it an ideal carrier in drug delivery.
20, 21, 22, 23
  
We have reported earlier about the formulat ion 
development aspects of crosslinked guar gum 
nanoparticles containing tamoxifen citrate and 
characterized the nanoparticles for morphology, drug-
polymer interaction, drug loading efficiency and drug 
release for finding its applicat ions in drug delivery  to 
cancer.
24,25 
In the present investigation, we have studied the 
internal morphology and shape of nanoparticles in TEM 
and anticancer efficacy of the drug loaded guar gum 
nanoparticles on Jurkat (human T-cell leukemia) cell line. 
Citrate salt was preferred to Tamoxifen free base due to its 
higher efficacy and the fact that commercially marketed 
products are manufactured with Tamoxifen citrate.  
MATERIALS AND METHODS  
Materials  
Central Drugs Laboratory, Kolkata, India generously 
supplied tamoxifen citrate as gift sample. Guar gum was 
purchased from Central Drug House, New Delh i, India. 
Span 80, and glycerol were procured from M/S Ranbaxy  
Ltd. Glutaraldehyde (25% aqueous solution) was procured 
from Sigma Chemicals, USA. All other solvents were of 
HPLC grade. Jurkat (human T-cell leukemia) cell line was 
obtained from National Centre for Cell Science (NCCS), 
Pune, India. WST-1(Cell pro liferation reagent) were 
purchased from Roche Diagnostics, Mannheim, Germany 
and RPMI 1640 (Roswell Park Memorial Institute medium 
1640), Fetal Bovine Serum, penicillin -G, Streptomycin, 
Gentamycin were procured from Invitrogen, Carlsbad, CA. 
Preparation of nanoparticles  
Guar gum nanoparticles containing tamoxifen citrate were 
prepared by oil in water emulsion in-situ polymer 
crosslinking technique.
24
 
Briefly 5mg of the drug 
tamoxifen citrate was taken in 10ml of d ichloromethane 
(DCM), this formed the oil phase. To this added 4 mg of 
Span 80 under stirring. The oil phase was then added to a 
0.5% aqueous guar gum solution under constant magnetic 
stirring. After mutual saturation of the oil and the 
continuous phase, the mixture was rapidly stirred. Glycerol 
(as stabilizer) was then added followed by addition of 25% 
glutaraldehyde solution to affect crosslinking under 
continuous stirring. Nanosuspension was kept overnight 
for nanoparticle formation. Nanoparticles were obtained 
after centrifugation at 20,000 rpm for 30minutes, washed 
with 15 ml HPLC grade water and recentrifuged. The 
yielded nanoparticles were lyophilized, harvested in micro  
centrifuge tubes and preserved in vacuum desiccators.  
CHARACTERIZATION OF TAMOXIFEN CITRATE 
LOADED GUAR GUM NANOPARTICLES  
Size distribution in TEM  
Transmission electron microscopy (FEI Technai 12 
BioTwin, The Netherlands) with a CCD camera mega 
view II soft imaging system was employed to visualize and 
record the nature and the size distribution of NPs. A 
generalized protocol was used for TEM studies.
26
 A drop 
of water suspension of the GG NPs was mounted on a 
carbon coated copper grid (CCG) and air-dried and micro  
graphed at 80-100kV (fig. 1). 
 In vitro cytotoxicity analysis of free tamoxifen citrate 
and tamoxifen citrate loaded guar gum nanoparticles 
on Jurkat (human T-cell leukemia) cell lines 
Jurkat (human T-cell leukemia) cells (Nat ional Centre for 
Cell Science (NCCS), Pune, India) were cu ltured in RPMI 
1640(Roswell Park Memorial Institute medium 1640) was 
used at pH 7.4, supplemented with 10% Fetal Bovine 
Serum and antibiotics (100U/ml penicillin -G, 100μg/ml-
sterptomycin, 6μg/ml Gentamycin). The cells were 
incubated at 37
0
C in a humidified atmosphere containing 
5% CO2 inside a CO2 incubator. 
WST-1 assay:  
The antiproliferative assay was carried out using the 
commercially available colorimetric assay kit WST-1 (Cell 
proliferation reagent, Roche, Germany). The cells (5 X10
4
 
cells in 100 µl medium/well) were plated in 0.05% DMSO 
in media as control in 96-well plates. The cells as such or 
in the presence of varying concentration of free tamoxifen  
citrate and loaded NPs (dissolved in 0.5%  DMSO in 
media) were incubated for 48 h. At the end of the 
treatments, each well was treated with WST-1 solution (10 
µl), and after incubation for 2 h, the absorption at 450 nm 
was read with a microplate reader (BIOTEK; ELX 800, 
USA). The inhibition of cell pro liferation by TMX and 
TMX loaded GG NPs was evaluated by calculating the 
IC50 values. 
 
Where A control, A treated are the absorbances of control and 
free TMX and TMX loaded GG NPs.  
RES ULTS AND DISCUSS ION  
In the present study tamoxifen citrate loaded guar gum 
nanoparticles in the size range of 200-300nm were 
prepared via a oil in water emulsion insitu polymer 
crosslinking technique.  Transmission electron microscopy 
analysis of drug loaded NPs were spherical with a dense 
TMX core (Fig. 1). Average TEM diameter was observed 
to be 205 nm. The antiproliferative action of free 
tamoxifen cit rate and tamoxifen citrate loaded guar gum 
nanoparticles was investigated on Jurkat (human T-cell 
leukemia) cell line. For this purpose pure drug and drug 
loaded nanoparticles were applied on the cancer cells in-
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vitro against a control experiment with cancer cells in the 
culture media without the free drug and nanoparticles. 
 
 
Figure 1: TEM micrograph of TMX loaded guar gum 
nanoparticles 
The microscopic images of control cells without any drug 
exposure and cells incubated with empty guar gum 
nanoparticles did not show any cell death, where as the 
images of cells treated with encapsulated and free 
tamoxifen citrate exh ib ited cell death (Figure 3a -3b). A  
dose dependent cytotoxicity was observed with TMX and 
TMX loaded GG NPs (table1 and figure 2). The cell 
morphology was observed and no loss in cellu lar 
morphology was found when cells were treated with empty 
GG NPs but significant changes were found after treatment 
with free TMX and TMX loaded guar gum nanocarriers. 
Loss of aggregation and lysis of cells were observed under 
these conditions as presented in figure 3a-3b.  
Since, guar gum is nontoxic and is approved by FDA for 
pharmaceutical applicat ions, it is expected that the drug 
loaded guar gum nanoparticles should be biocompatible, 
biodegradable and potentially safe as a drug carrier for 
clin ical use. In vitro cytotoxicity assay proved that empty 
nanocarriers showed no cytotoxicity and TMX loaded 
nanoparticles was as effective as free TMX. It is observed 
that there is significant change in morphology of the cells 
after treatment with TMX and TMX loaded nanoparticles 
suggesting effectiveness of TMX loaded guar gum 
nanoparticles on the experimental cell line and eliminating 
the probability of plain guar gum induced cytological 
changes in the present investigation.  
 
Table 1: Percent death of Jurkat cells with free TMX and TMX loaded GG NPs after 48 h incubation in RPMI-1640 
medium. 
S. 
No 
Concentration 
μM 
A control 
(only cell 
in media) 
 
A treated %Cell Death  
Cell  
+ 
TMX 
Cell  
+  
NPs 
Free TMX TMX loaded NPs 
1 10 2.0 0.545 1.827 41 10 
2 25 2.0 0.227 0.293 83.21 77.45 
3 50 2.0 0.214 0.289 89.46 85.76 
4 100 2.0 0.184 0.331 90.94 83.69 
5 150 2.0 0.171 0.369 91.45 81.82 
                       *A stands for Absorbance 
It is evident from table1 and figure 2 that the trend of % 
cell death tends to decrease at nanoparticle dose of 50 μM 
and more. One possible explanation for this fact may be a 
progressive saturation of the endocytotic process with time 
suggesting a saturable kinetics for the  transport of 
nanoparticles.
27 
The cellular uptake of guar gum 
nanoparticles may be assumed to be mediated by non 
specific endocytotic process rather than receptor mediated. 
Similar results were observed by Amiji et al.
28 
The 
inhibitory IC50 for both free TMX and TMX loaded GG 
NPs was found to be below 25μM. Based on the saturation 
of the endocytotic process for the nanoparticles, it may be 
assumed that at higher doses of nanoparticles (50μM and 
more) the intercellular Tamo xifen concentration was not as 
high as it should be resulting in the reduced rate of cell 
death of the cells. The cellu lar uptake o f free drug however 
can occur either by passive diffusion and pinocytosis.,
29 
Pinocytosis main ly performs the capture of 
macromolecules adherent to the surface membrane. The 
size of an average pinocytic vesicle is about 100 to 200 
nm.
30
 It may further be assumed that the free drug solution 
will be distributed all over the body whereas the NPs (200-
300nm) may be preferentially distributed in the tumor 
tissue because of the EPR effect. Leaky vasculature and 
lack of effect ive lymphatic drainage from the tumour 
results in the extravasation and accumulation of 
particulates, plasma proteins and other macromolecules.
31 
This trapping of macromolecu les has been termed the 
“enhanced permeability and retention” (EPR).32,33 EPR 
effect is now thought to contribute to the effects of many 
anticancer drugs delivered as conjugates with synthetic 
polymers
34,35 
or in liposomes.
36 
Mechanism of action for 
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highly protein bound drugs (anthracylcines, paclitaxel, 
etoposide) also seems to be mediated through the EPR.
37
 
However, the cut-off size of the permeable vasculature 
varies from tumour to tumour, and the size of a drug 
carrying particle may be used to control the passive drug 
delivery.
38
 Doxorubicin incorporated into long circulating 
pegylated liposomes showed excellent tumour 
accumulat ion through EPR and reduced side effects of 
doxorubicin.
39,40 
 With the support of the established 
literature we may assume that the prepared guar gum 
nanoparticles of 200-300nm size are preferentially  
accumulated on the Jurkat cells by EPR effect and is 
expected to increase the concentration of drug inside the 
tumor cells as a result of a nonspecific endocytotic 
process, followed by a gradual release of the drug and 
binding of tamoxifen to the estrogen receptor around the 
nucleus to produce the desired antitumor effect. 
 
Figure 2: Showing cell death with free TMX and TMX loaded guar gum nanoparticles after 48 h incubat ion in RPMI-1640 
medium 
                            
        Figure 3a: TMX loaded GG NPs x 48 hrs(Jurkat Cells)          Figure 3b: TMX x 48 hrs (Jurkat Cells) 
Under these conditions the formulations of predesigned 
nanoparticles with calculated process parameter may be 
very efficient tool for intercellular delivery  of anticancer 
drugs like tamoxifen cit rate. These results demonstrated 
that this delivery system could be a promising choice for 
administering tamoxifen citrate without loss of its 
therapeutic efficacy.  
CONCLUS ION  
Nanoparticles by virtue of its size and properties are 
potential tools for treating cancer. Guar gum nanoparticles 
containing tamoxifen citrate under the present 
investigation exhibited the benefits of nanoencapsulation 
for highly p rotein binding drug tamoxifen citrate in passive 
targeting of cancer. The drug loaded nanoparticles were as 
efficient as the free drug when applied to the cancer cells. 
However, the crosslinked guar gum nanoparticles loaded 
with tamoxifen cit rate exhib ited sustained release of the 
drug and delayed apoptosis over a long period of time 
making it suitable for cancer treatment.  
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